PURPOSE: We used the Female Sexual Function Index (FSFI) to investigate the prevalence of sexual dysfunction (SD) and factors associated with diminished sexual functioning in early stage endometrial cancer (EC) patients treated with simple hysterectomy and adjuvant brachytherapy. METHODS AND MATERIALS: A cohort of 104 patients followed in a radiation oncology clinic completed questionnaires to quantify current levels of sexual functioning. The time interval between hysterectomy and questionnaire completion ranged from <6 months to >5 years. Multivariate regression was performed using the FSFI as a continuous variable (score range, 1.2-35.4). SD was defined as an FSFI score of <26, based on the published validation study. RESULTS: SD was reported by 81% of respondents. The mean (± standard deviation) domain scores in order of highest-to-lowest functioning were: satisfaction, 2.9 (± 2.0); orgasm, 2.5 (± 2.4); desire, 2.4 (± 1.3); arousal, 2.2 (± 2.0); dryness, 2.1 (± 2.1); and pain, 1.9 (± 2.3). Compared to the index population in which the FSFI cut-score was validated (healthy women ages 18-74), all scores were low. Compared to published scores of a postmenopausal population, scores were not statistically different. Multivariate analysis isolated factors associated with lower FSFI scores, including having laparotomy as opposed to minimally invasive surgery (effect size, -7.1 points; 95% CI, -11.2 to -3.1; P<.001), lack of vaginal lubricant use (effect size, -4.4 points; 95% CI, -8.7 to -0.2, P=.040), and short time interval (<6 months) from hysterectomy to questionnaire completion (effect size, -4.6 points; 95% CI, -9.3-0.2; P=.059). CONCLUSIONS: The rate of SD, as defined by an FSFI score <26, was prevalent. The postmenopausal status of EC patients alone is a known risk factor for SD. Additional factors associated with poor sexual functioning following treatment for EC included receipt of laparotomy and lack of vaginal lubricant use.
PURPOSE: We used the Female Sexual Function Index (FSFI) to investigate the prevalence of sexual dysfunction (SD) and factors associated with diminished sexual functioning in early stage endometrial cancer (EC) patients treated with simple hysterectomy and adjuvant brachytherapy. METHODS AND MATERIALS: A cohort of 104 patients followed in a radiation oncology clinic completed questionnaires to quantify current levels of sexual functioning. The time interval between hysterectomy and questionnaire completion ranged from <6 months to >5 years. Multivariate regression was performed using the FSFI as a continuous variable (score range, 1.2-35.4). SD was defined as an FSFI score of <26, based on the published validation study. RESULTS:SD was reported by 81% of respondents. The mean (± standard deviation) domain scores in order of highest-to-lowest functioning were: satisfaction, 2.9 (± 2.0); orgasm, 2.5 (± 2.4); desire, 2.4 (± 1.3); arousal, 2.2 (± 2.0); dryness, 2.1 (± 2.1); and pain, 1.9 (± 2.3). Compared to the index population in which the FSFI cut-score was validated (healthy women ages 18-74), all scores were low. Compared to published scores of a postmenopausal population, scores were not statistically different. Multivariate analysis isolated factors associated with lower FSFI scores, including having laparotomy as opposed to minimally invasive surgery (effect size, -7.1 points; 95% CI, -11.2 to -3.1; P<.001), lack of vaginal lubricant use (effect size, -4.4 points; 95% CI, -8.7 to -0.2, P=.040), and short time interval (<6 months) from hysterectomy to questionnaire completion (effect size, -4.6 points; 95% CI, -9.3-0.2; P=.059). CONCLUSIONS: The rate of SD, as defined by an FSFI score <26, was prevalent. The postmenopausal status of EC patients alone is a known risk factor for SD. Additional factors associated with poor sexual functioning following treatment for EC included receipt of laparotomy and lack of vaginal lubricant use.
Authors: Lois C Friedman; Rita Abdallah; Mark Schluchter; Ashok Panneerselvam; Charles A Kunos Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-07 Impact factor: 7.038
Authors: Kaled M Alektiar; Ennapadam Venkatraman; Dennis S Chi; Richard R Barakat Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-01 Impact factor: 7.038
Authors: Michael Frumovitz; Charlotte C Sun; Leslie R Schover; Mark F Munsell; Anuja Jhingran; J Taylor Wharton; Patricia Eifel; Therese B Bevers; Charles F Levenback; David M Gershenson; Diane C Bodurka Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Gregory Spiegel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small Journal: Brachytherapy Date: 2016-05-31 Impact factor: 2.362
Authors: Maria Ida Maiorino; Paolo Chiodini; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito Journal: Endocrine Date: 2015-12-07 Impact factor: 3.633
Authors: Laura B Huffman; Ellen M Hartenbach; Jeanne Carter; Joanne K Rash; David M Kushner Journal: Gynecol Oncol Date: 2015-11-07 Impact factor: 5.482
Authors: Marisa R Moroney; Dina Flink; Jeanelle Sheeder; Erin A Blake; Aakriti R Carrubba; Christine M Fisher; Saketh R Guntupalli Journal: Rep Pract Oncol Radiother Date: 2018-08-13
Authors: Christina M Wilson; Deborah B McGuire; Beth L Rodgers; R K Elswick; Sarah M Temkin Journal: Cancer Nurs Date: 2021 Sep-Oct 01 Impact factor: 2.592